Prelude Therapeutics (PRLD) Stock Price, News & Analysis

Company Overview

Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company uses cancer biology, medicinal chemistry and targeted drug-discovery approaches to identify small-molecule therapies designed to address genetic and molecular vulnerabilities in tumors.

Prelude’s investigational pipeline has included PRT3789, a selective SMARCA2 protein degrader being developed for cancers with SMARCA4 loss, and PRT2527, a selective cyclin-dependent kinase 9 (CDK9) inhibitor under evaluation for oncology applications. These programs are investigational and are not approved for commercial use.

Founded in 2016 and headquartered in Wilmington, Delaware, Prelude conducts research and clinical development activities in the United States. The company was founded by David Mack, Ph.D., who has served as its president and chief executive officer. As a clinical-stage biotechnology company, Prelude’s operations are primarily focused on advancing its drug candidates through clinical testing and establishing potential treatment options for patients with cancer.

Key Stats

• Today's Range: $3.85 to $4.03
• 50-Day Range: $3.67 to $6.63
• 52-Week Range: $1.15 to $6.83
• Volume: 341,648 shs
• Average Volume: 516,939 shs
• Market Capitalization: $310.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.75
• Consensus Rating: Moderate Buy

Prelude Therapeutics Stock Analysis - MarketRank™

Prelude Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 640th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Prelude Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Prelude Therapeutics has a consensus price target of $8.75, representing about 124.9% upside from its current price of $3.89.

Amount of Analyst Coverage

Prelude Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Prelude Therapeutics are expected to decrease in the coming year, from ($0.61) to ($0.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prelude Therapeutics is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prelude Therapeutics is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Prelude Therapeutics has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.29% of the float of Prelude Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Prelude Therapeutics has a short interest ratio ("days to cover") of 7.91.

Change versus previous month

Short interest in Prelude Therapeutics has recently increased by 26.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prelude Therapeutics does not currently pay a dividend.

Dividend Growth

Prelude Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

Prelude Therapeutics has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Prelude Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for PRLD on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Prelude Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

49.20% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PRLD
• CIK: 1678660
• Web: www.preludetx.com
• Phone: 302-467-1280
• Fax: N/A
• Employees: 79
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Prelude Therapeutics: $8.75
• High Price Target: $12.00
• Low Price Target: $6.00
• Potential Upside/Downside: +124.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$99.50 million
• Net Margins: N/A
• Pretax Margin: -338.98%
• Return on Equity: -75.35%
• Return on Assets: -44.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.07
• Quick Ratio: 4.07

Sales & Book Value

• Annual Sales: $12.14 million
• Price / Sales: 25.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 79,800,000
• Free Float: 40,540,000
• Market Cap: $310.42 million
• Optionable: Optionable
• Beta: 0.97